Non-Interventional Post-Authorisation Safety Study (PASS) survey to evaluate the effectiveness of the Isatuximab Educational Materials, to minimise the Risk of Interference for blood typing (minor antigen) (positive indirect Coombs’ test).
Non-Interventional Post-Authorisation Safety Study (PASS) survey to evaluate the effectiveness of the Isatuximab Educational Materials, to minimise the Risk of Interference for blood typing (minor antigen) (positive indirect Coombs’ test).